ShowBiz & Sports Lifestyle

Hot

Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again

Eli Lilly is trouncing Nvidia — and the weight-loss drug trade is beating AI again

Jared BlikreMon, November 16, 2026 at 5:05 PM UTC

0

Wall Street put the AI trade on a diet six weeks ago. The maker of Zepbound has been doing the bulking up.

Since its Oct. 6 record, Nvidia (NVDA) has shed more than $1.7 trillion in market value. Eli Lilly (LLY) has added more than $250 billion over the same stretch, a gain topped only by Apple (AAPL) among the market's biggest stocks.

That's a 25% gain for the maker of Zepbound and Mounjaro against a 32% drop for the AI chip king through Friday's close. The gap kept widening Monday, a day before Nvidia's first earnings report since Jensen Huang's exit.

And it's not just one matchup. The AI trade has been bleeding from every direction since Nvidia peaked, with Alphabet (GOOGL) shedding about $640 billion in market value, SpaceX (SPCX) about $450 billion, and Micron (MU) about $300 billion, by Yahoo Finance calculations. Apple, Lilly, and Walmart (WMT) have been collecting.

It's the same lineup that showed up in October, when AI stocks lost about $5 trillion in less than a month and Lilly topped the winners' list.

Remember the GLP-1 trade?

Early in this bull market, the weight-loss drugmakers were Wall Street's other obsession. In the 15 months after the October 2022 low, Lilly and Novo Nordisk (NVO) gained about 92% on average, within shouting distance of the Magnificent Seven's 101%.

Then it fell apart. Novo lost about three-quarters of its value from its June 2024 peak, and the GLP-1 trade spent two years watching Big Tech run off with the bull market.

Advertisement

Now the roles have reversed. Lilly just pulled ahead of Nvidia over the past five years. The price tags have flipped too, with Lilly at roughly 27 times forward earnings, about two and a half times Nvidia's multiple, according to Yahoo Finance data.

Eli Lilly's stock has pulled ahead of Nvidia's over the past five years.

The two worlds collided last week. In a video pitching Anthropic's IPO, CEO Dario Amodei said, "Cancer, Alzheimer's, heart disease, mental illness — these will be relics of the past in, I think, less than a decade."

Lilly CEO Dave Ricks wasn't buying it. "I think that would be amazing and I think it's not likely," he wrote on X, adding that "progress will likely be steady and incremental."

Lilly's run looks stretched

That doesn't necessarily make the weight-loss trade the one to chase now. Lilly stock sits about 30% above its 200-day moving average, the average of its last 200 closing prices.

Running that hot is nothing new for Lilly in this bull market. It's happened about one in seven trading days, nearly three times as often as in the years before. In 2023 and early 2024, even hotter streaks ended in dips of 7% to 12%. The last two ended in drops of more than 20%.

BofA's Michael Hartnett sees the market's hiding places as the crowded side of the trade. In a recent report, he put healthcare among the groups "most vulnerable to downside" and named "semis, discretionary, homebuilders" as "most vulnerable to upside next 8 weeks."

Internal AI tools helped analyze interview transcripts, research, and draft this post. Humans reviewed, edited, and fact-checked this post before publication.

Jared Blikre is the global markets and data editor for Yahoo Finance. Follow him on X at @SPYJared or email him at jaredblikre@yahooinc.com.

Original Article on Source

Source: “AOL Money”

We do not use cookies and do not collect personal data. Just news.